Table 1 Patient characteristics gout cohort
From: Neutrophil activation identifies patients with active polyarticular gout
Characteristics | Gout cohort (N = 75) | Control group (N = 30) |
|---|---|---|
Gender (N, % male) | 68 (89.5%) | 14 (46.7%) |
Age in years (mean, SD) | 58 (± 11.7) | 49 (± 15.2) |
Disease duration in years (median, IQR) | 4 [2–10] | N.A. |
Mono-articular gout (N, %) | 22 (29%) | N.A. |
Poly-articular gout (N, %) | 53 (71%) | N.A. |
Subcutaneous tophi (N, %) | 22 (29%) | N.A. |
VAS pain (median, IQR) | 11 [1–45] | N.A. |
VAS disease activity (median, IQR) | 19 [1–48.5] | N.A. |
RAPID score total (median, IQR) | 4.3 [1.8–6.0] | N.A. |
Urate lowering therapy (N, %) | 49 (66%) | N.A. |
Smoking, yes (N, %) | 13 (17.1%) | 5 (17%) |
BMI (mean, SD) | 30.4 (± 4.9) | 24.1 (± 3.2) |
Serum urate (mmol/L) (mean, SD) | 0.42 (± 0.09) | N.D. |
BSE [median, IQR] | 7 [4.5–10.5] | N.D. |
CRP [median, IQR] | 2.2 [1.1–3.7] | N.D. |
Creatinine (mean, SD) | 98.6 (28.3) | N.D. |
ALAT (mean, SD) | 37.5 (18.8) | N.D. |